VahatiCor New CEO: Endotronix Co-Founder Harry D. Rowland Takes the Helm to Advance CMD Therapy

By Editorial Team On May 18, 2026

VahatiCor, a medtech company developing interventional therapies for Coronary Microvascular Dysfunction, announced the appointment of Harry D. Rowland, Ph.D., as Chief Executive Officer. The VahatiCor new CEO brings a resume built on exactly the kind of work this company needs: he co-founded Endotronix, guided its flagship device to FDA approval, and navigated the company’s acquisition by a global healthcare giant — all before turning his sights to VahatiCor’s mission. That mission is urgent.

Approximately 3 to 4 million Americans suffer from ischemia and angina with nonobstructive coronary artery disease — a population trapped in a frustrating diagnostic loop where chest pain persists despite clean large-artery scans. These patients often cycle through the healthcare system without receiving effective relief. With the VahatiCor new CEO now firmly in place, the Santa Clara-based company is better positioned than ever to build the clinical and regulatory foundation for a device that could genuinely change that reality.

What the VahatiCor New CEO Appointment Means for Medtech in 2026

Timing matters enormously in device development, and the VahatiCor Harry Rowland appointment today lands at a genuine inflection point. VahatiCor is enrolling patients in SERRA-I, its early feasibility study of the A-FLUX Reducer System, while preparing for SERRA-II and advancing engineering, clinical, regulatory, and commercial initiatives. The SERRA-I early feasibility study will include 30 patients across six sites. Bringing in a CEO of Rowland’s caliber at this exact stage is a signal of strategic intent, not a routine hire.

Brian R. Smith, Managing Director at S3 Ventures, commented: “Harry is the right leader for VahatiCor at this pivotal stage, when breakthrough technology requires disciplined execution. A-FLUX represents a substantial opportunity to reach a large, underserved patient population, and Harry brings the proven ability to build the team, clinical evidence, and operational foundation needed to move that opportunity forward.” S3 Ventures led VahatiCor’s oversubscribed $23 million Series B financing in November 2025, joined by Intuitive Ventures and a strategic investor. The capital was deployed toward advancing SERRA-I enrollment, engineering development, and preparation for subsequent studies, including planning for pivotal trials and regulatory interactions.(.)

Days after the Harry D. Rowland medtech CEO news broke, VahatiCor will participate in EuroPCR 2026 in Paris, France, from May 19 to 22, hosting a scientific symposium titled “Early Evidence from a Next-Generation Coronary Sinus Reducer for the Treatment of Coronary Microvascular Dysfunction” on Wednesday, May 20. Announcing the VahatiCor Harry Rowland appointment today — just before this global cardiology stage — puts a formidable new face on an already compelling clinical story.

VahatiCor Harry Rowland Appointment Today: The Endotronix Story Behind the Hire

The endotronix founder Harry Rowland VahatiCor connection is not just a career footnote. It is the entire strategic rationale for this appointment. Co-founded in 2007 by Harry Rowland, Ph.D., and cardiothoracic surgeon Dr. Anthony Nunez, the pair sought to develop an implantable, wireless pressure sensor platform to help manage cardiovascular health. That idea became the Cordella Pulmonary Artery Sensor and Heart Failure System — a device designed to allow remote management of heart failure through real-time pulmonary artery pressure monitoring.

Rowland led Endotronix from concept through every critical milestone. He previously served as Chief Executive Officer and President of Endotronix, where he led the development and commercialization of the Cordella Pulmonary Artery Sensor and Heart Failure System. The Cordella system was approved by the U.S. Food and Drug Administration in June 2024, just weeks before Endotronix was acquired by Edwards. According to data from the PROACTIVE-HF study, treatment with the Cordella system was associated with significantly reduced risks of all-cause mortality and heart failure hospitalization after one year.

Rowland also oversaw the PROACTIVE-HF pivotal trial from execution through FDA premarket approval and commercial launch. Following its acquisition by Edwards Lifesciences in 2024, he stayed on to support key CMS national coverage and CE Mark milestones. That full-cycle story — from founding through FDA clearance through acquisition and post-deal integration — defines what VahatiCor is buying with this hire. He received his PhD in mechanical engineering from the Georgia Institute of Technology and a BS in mechanical engineering and MA in economics from the University of California, Santa Barbara. Both credentials matter here: the engineering PhD fuels technical credibility in the lab, while the economics master’s degree brings the financial discipline a clinical-stage company needs. The endotronix founder Harry Rowland VahatiCor partnership is, in that sense, entirely deliberate.

VahatiCor CMD Heart Therapy News: Understanding Why This Disease Needs a Champion

The VahatiCor CMD heart therapy news gets its urgency from the staggering, underappreciated burden of CMD itself. CMD occurs when the small coronary arteries within the heart muscle fail to dilate properly upon exertion, reducing blood flow to the heart muscle and creating discomforting angina symptoms. Patients experience pressure, tightness, and chest pain — sometimes for years — while being told their coronary arteries look perfectly clear. Conventional stenting and bypass surgery offer this population nothing.

The stakes are life-and-death serious. Millions of CMD patients worldwide suffer from persistent chest pressure, tightness, and chest pain, with no current viable options for symptom relief. Left untreated, a CMD diagnosis results in a fourfold elevated mortality risk compared to the general population. A systematic meta-analysis spanning 14,427 patients published in the Journal of the American Heart Association found a pooled CMD prevalence of 41% among patients with angina and nonobstructive coronary arteries. Women shoulder a disproportionate share of that burden: a 2025 evidence review identified coronary microvascular dysfunction as a prevalent, high-risk condition affecting 41% of patients with angina and non-obstructive coronary arteries, with women facing a 45% higher risk of developing this condition. Recent meta-analyses demonstrate that CMD doubles cardiovascular risk with hazard ratios of 2.08–2.45.

CMD is associated with considerable risk of major adverse cardiac events including heart failure, myocardial infarction, stroke, and death — yet current medications fail in more than half of CMD patients, leaving a massive therapeutic void. That gap is the foundation of the entire VahatiCor CMD heart therapy news story, and Rowland now leads the company working hardest to close it.

VahatiCor A-FLUX Reducer System Update: What the Technology Actually Does

The VahatiCor A-FLUX Reducer System update going into Rowland’s tenure starts from a position of genuine clinical momentum. The A-FLUX hourglass-shaped implant, placed in the coronary sinus, is designed to increase blood flow to the microvasculature, reducing persistent chest pain and improving overall quality of life. As a coronary sinus reducer, the device creates a controlled narrowing of the coronary sinus, optimizing and redistributing oxygenated blood flow to support and enhance perfusion and relieve angina symptoms.(.)

The A-FLUX runs on SwiftCell Technology, a small-cell proprietary design based on computational modeling, to redistribute oxygen supply to the sub-endocardium layer of the heart muscle. Full retrievability and atraumatic expansion distinguish it from earlier-generation devices. Early research concluded that the next-generation self-expanding coronary sinus reducer demonstrates procedural safety coupled with promising short-term clinical efficacy in persistently symptomatic patients with either obstructive epicardial CAD or nonobstructive epicardial coronaries with CMD. That research, published in JSCAI, reflects an independent assessment of the device’s early profile.

The short implantation procedure time — averaging just nine minutes — and clinical outcomes of the A-FLUX Reducer System highlight its potential to become a frontline device therapy for patients with persistently symptomatic CMD. Patients treated with the A-FLUX Reducer System reported rapid symptom improvements and returned to their daily activities with minimal recovery time. Those results launched SERRA-I, co-led by Samit Shah, MD, PhD, from Yale School of Medicine and Tim Van de Hoef, MD, PhD, from University Medical Center Utrecht. The VahatiCor A-FLUX Reducer System update, with SERRA-I actively enrolling and SERRA-II in planning, is precisely what Rowland has been brought in to advance.

Key Milestones Ahead Under VahatiCor’s New CEO

With the VahatiCor new CEO now leading daily operations, the company’s near-term roadmap is well-defined and ambitious:

SERRA-I enrollment: Actively enrolling 30 patients across six U.S. clinical sites, evaluating A-FLUX safety and efficacy in patients with persistent symptomatic CMD, co-led by Yale School of Medicine and University Medical Center Utrecht.
EuroPCR 2026 symposium: VahatiCor presents early clinical evidence from a next-generation coronary sinus reducer in Paris on May 20, 2026, before an international interventional cardiology audience.
SERRA-II preparation:Pivotal trial groundwork: Engineering, regulatory, clinical, and commercial infrastructure advancing in parallel to prepare for future FDA interactions and pivotal study filings.
Evidence-building partnerships: Deepening collaborations with physician investigators to support adoption and eventual regulatory submissions.

Every step on that list is one Rowland has completed before — the Harry D. Rowland medtech CEO news carries weight precisely because his track record maps directly onto VahatiCor’s specific needs.

VahatiCor CEO Announcement May 2026: What the Industry Is Saying

The VahatiCor CEO announcement May 2026 drew strong responses from both the founding team and lead investors. VahatiCor co-founder Marwan Berrada-Sounni stated: “Harry has led a medical company through this arc before. He took Endotronix from clinical concept to FDA approval and subsequent acquisition by Edwards Lifesciences, building both the team and the supporting evidence base. As VahatiCor advances A-FLUX and continues to generate evidence for patients with Coronary Microvascular Dysfunction, we are confident that Harry is the right leader to bring this therapy forward.”

Terri Burke, Senior Partner at Intuitive Ventures, highlighted that “the high symptom burden of recurring angina, reduced exercise capacity, diminished quality of life, and psychological distress caused by delayed diagnosis demands more clinical awareness and effective therapies that prioritize the patient experience.” That framing captures exactly why the VahatiCor CEO announcement May 2026 resonates far beyond the boardroom. Rowland himself noted that he was “immediately drawn to VahatiCor as a promising alternative treatment option for patients suffering from persistent chest pain,” adding that the A-FLUX design “is designed to increase blood flow to the microvasculature, reducing this pain and improving overall quality of life.”

A Leadership Bet That Could Change Cardiology for Millions

The VahatiCor new CEO appointment is more than a personnel announcement. It is a declaration that VahatiCor is serious about the clinical, regulatory, and commercial work required to bring an approved therapy to millions of CMD patients who currently have nothing effective to reach for.

Rowland led Endotronix’s operations, strategy, and technology development since inception, and his vision was integral in raising $100 million in VC and strategic financing while building the company to over 70 people. That rare combination of scientific conviction, fundraising credibility, and operational discipline is exactly what a company at this clinical stage requires. CMD has been an orphan disease in interventional cardiology for too long. If this VahatiCor new CEO delivers anything close to what he delivered at Endotronix, that orphan status may finally be drawing to a close.

Frequently Asked Questions

Who is Harry D. Rowland, the VahatiCor new CEO?

Harry D. Rowland, Ph.D., is a medtech entrepreneur and engineer who co-founded Endotronix in 2007 alongside cardiothoracic surgeon Dr. Anthony Nunez. He served as CEO of Endotronix from its earliest days, steering the company through FDA approval of the Cordella Pulmonary Artery Sensor System in June 2024 and its subsequent acquisition by Edwards Lifesciences. He holds a PhD in Mechanical Engineering from Georgia Tech and a master’s in Economics from UC Santa Barbara.

What is Coronary Microvascular Dysfunction (CMD)?

CMD is a heart condition in which the small coronary arteries within the heart muscle fail to dilate properly upon exertion, reducing blood flow and causing persistent angina — despite the absence of blockages in the larger coronary arteries. It affects an estimated 3 to 4 million Americans, disproportionately impacts women, and carries a fourfold elevated mortality risk when left untreated. Current medications fail in more than half of patients.

What is the VahatiCor A-FLUX Reducer System?

The A-FLUX Reducer System is an investigational, hourglass-shaped nitinol implant placed in the coronary sinus — the heart’s largest vein. It creates a controlled narrowing of the coronary sinus to redistribute oxygenated blood flow to ischemic microvascular tissue, aiming to relieve persistent chest pain in CMD patients. It is built on proprietary SwiftCell Technology, features atraumatic expansion and full retrievability, and averages a nine-minute implant procedure time.

What is the SERRA-I study?

SERRA-I is VahatiCor’s U.S. early feasibility study of the A-FLUX Reducer System, exclusively focused on patients with persistent symptomatic CMD. The study plans to enroll 30 patients across six clinical sites. Co-principal investigators are Samit Shah, MD, PhD, from Yale School of Medicine, and Tim Van de Hoef, MD, PhD, from University Medical Center Utrecht in the Netherlands.

When was the VahatiCor CEO announcement made?

VahatiCor formally announced the appointment of Harry D. Rowland, Ph.D., as Chief Executive Officer on May 17, 2026, via a press release through Business Wire. The announcement came just days ahead of VahatiCor’s participation in EuroPCR 2026 in Paris, France, where the company is hosting a scientific symposium on May 20, 2026.

Who are VahatiCor’s investors?

VahatiCor closed an oversubscribed $23 million Series B financing in November 2025, led by S3 Ventures — one of the largest and longest-serving venture capital firms in Texas — with additional support from Intuitive Ventures and a strategic investor. The capital is being deployed to advance SERRA-I enrollment, engineering development, and preparation for pivotal trials.

How does Rowland’s background at Endotronix prepare him for VahatiCor’s clinical pathway?

Rowland’s experience at Endotronix mirrors precisely what VahatiCor needs next. He guided Endotronix through a pivotal clinical trial (PROACTIVE-HF), obtained FDA premarket approval for the Cordella system, and oversaw its commercial launch before supporting CMS national coverage and CE Mark milestones post-acquisition. That end-to-end experience — from early feasibility study through pivotal trial through regulatory approval — maps directly onto VahatiCor’s development roadmap for the A-FLUX Reducer System.